沙美特罗替卡松与孟鲁司特钠联用治疗中重度支气管哮喘的效果观察

Observation of the efficacy of salmeterol/fluticasone and montelukast sodium on moderate to severe bronchial asthma

目的观察中重度支气管哮喘患者联用沙美特罗替卡松、孟鲁司特钠治疗的疗效。方法选取2014年1月至2016年12月山西省煤炭中心医院进行治疗的170例中重度支气管哮喘患者,将患者分为两组,每组85例。对照组使用沙美特罗替卡松治疗,观察组在对照组的基础上联用孟鲁司特钠。结果治疗后,观察组治疗有效率为95.29%,对照组治疗有效率为82.35%,差异有统计学意义(P<0.05),且观察组患者的用力肺活量(FVC)、第一秒用力呼气容积(FEV1)、最大呼气流量(PEF)等肺功能指标均优于对照组,白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)等血清炎性因子水平低于对照组,差异有统计学意义(P<0.05)。结论对中重度支气管哮喘患者采取孟鲁司特钠、沙美特罗替卡松联用治疗能够改善患者肺功能,降低炎性因子水平,提升临床疗效,具有推广价值。

Objective To observe the efficacy of salmeterol and montelukast sodium on moderate and severe bronchial asthma.Methods A total of 170 patients with moderate to severe bronchial asthma treated in Shanxi Coal Central Hospital from January 2014 to December 2016 were enrolled.The patients were divided into two groups,with 85 cases in each group.Patients in control group were treated with salmeterol,and patients in observation group were treated with montelukast sodium on the basis of salmeterol.Results After treatment,the effective rate in the observation group was 95.29%,and the effective rate in the control group was 82.35%,and the difference was significant(P<0.05).And the lung function indexes such as forced vital capacity(FVC),forced expiratory volume in one second(FEV1),and peak expiratory flow(PEF)were significantly better in the observation group(P<0.05).The serum inflammatory factors such as interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)were significantly lower in the observation group than those in the control group,and the differences were significant(P<0.05).Conclusions The combination of montelukast sodium and salmeterol and celecoxib for patients with moderate to severe bronchial asthma can improve the lung function,reduce the inflammatory factor levels and improve the clinical efficacy,which is worthy of popularization.